Article Text

other Versions

PDF
Adalimumab; a new modality for Behçet’s disease?
  1. J AM van Laar (j.vanlaar{at}erasmusmc.nl)
  1. Erasmus University Medical Center, Netherlands
    1. T Missotten (missotten{at}oogziekenhuis.nl)
    1. Eye Hospital, Netherlands
      1. P LA van Daele (p.l.a.vandaele{at}erasmusmc.nl)
      1. Erasmus University Medical Center, Netherlands
        1. A Jamnitski (ajamnitski{at}hotmail.com)
        1. Erasmus University Medical Center, Netherlands
          1. G S Baarsma (baarsma{at}oogziekenhuis.nl)
          1. Eye Hospital, Netherlands
            1. P M van Hagen (p.m.vanhagen{at}erasmusmc.nl)
            1. Erasmus University Medical Center, Netherlands

              Abstract

              Aberrant T-cell function [1] subsequently accompanied by elevated TNF-α levels induces inflammatory symptoms in patients with Behçet’s disease (BD).[2, 3] Subsequently treatment usually involves T-cel directed immunosuppressive or anti-TNF-α therapy in patients with severe disease.[4] [5] [6] [7] Administration of the new human monoclonal TNF-α antibody adalimumab has only been described in three BD patients with uveitis.[8] We analyzed the effects of adalimumab on severe and often chronic disease in 6 heavily pretreated BD patients with immunosuppressive therapy failure (Table).

              • Behcet disease
              • TNF alpha inhibitor
              • adalimumab
              • infliximab

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.